Dentsply Sirona: What Analysts Recommend before 1Q17 Results
Dentsply Sirona (XRAY) is set to release its 1Q17 results on May 9, 2017. Let’s take a look at Wall Street analysts’ recommendations and target prices for the company over the next year. In a Reuters survey based on recommendations of 15 brokerage companies, Dentsply Sirona received “buy” ratings from ~53% of analysts and “hold” ratings from ~47% of analysts. Only one analyst issued a “sell” recommendation on XRAY stock.
Interested in ALGN? Don't miss the next report.
Receive e-mail alerts for new research on ALGN
The above chart provides a recommendation summary for Dentsply Sirona over the next year. The stock’s consensus 12-month target price is $67.33, which amounts to a ~3.1% return potential over XRAY’s price of $65.3 on May 4, 2017.
According to analysts’ most recent recommendations, the lowest one-year target price for Dentsply Sirona was $60. The target implies a return potential of -8% over the next 12 months. On the other hand, Dentsply Sirona’s highest one-year target price was $76, which implies an approximately 16.4% return potential over the next 12 months.
Peers Zimmer Biomet Holdings (ZBH), Integra LifeSciences Holdings (IART), and Align Technology (ALGN) have average broker target prices of ~$134.1, $50.9, and $146.5, respectively. These figures imply returns of 14.7%, 10.8%, and 3.2%, respectively, over the next 12 months.
ETFs with exposure to Dentsply Sirona
Investors interested in gaining focused exposure to Dentsply Sirona can consider investing in the SPDR S&P Health Care Equipment ETF (XHE). XHE invests 1.8% of its total holdings in Dentsply Sirona.
You can consider investing in healthcare sector ETFs such as the Health Care Select Sector SPDR ETF (XLV) for exposure to Dentsply Sirona. XLV has ~0.52% of its total holdings in Dentsply Sirona.
To reduce company-specific risks, you can also check out the iShares Core S&P 500 ETF (IVV), which has ~0.0.07% of its total portfolio in Dentsply Sirona.